Third Circuit Accepts Preemption Arguments; More Cautions About Follow-On Biologics; Health Canada Issues Approval Guidance; FDA Takes First Steps in Expanding Drug Safety; Congress Proposes Requiring “Country of Origin” Statement; Congress Wants Direct Treatment Comparisons; Further Congressional Questions About Drug Advertising; Promised Studies Not Done; Warning over Avandia; Inspections of Foreign Facilities Will Not Be Easy; FDA Guidance on Genomics Term Definitions; European Scientists Want More Nanotechnology Regulation; Geron Stem Cell Trial on Hold; South Korea Clarifies Cloning Regulations; Decisions Needed on Antivirals in Advance of Flu Epidemic; Efforts to Control Genetic Testing; Bush Signs Genetic Information Nondiscrimination Act; Drug Companies Petition for Looser Restrictions on Literature on Off-Label Uses; Merck Said to Have Violated Publishing Ethics; Trade in Biotechnology Requires Closer Control; U.N. Alleges Chinese Dissidents Being Used as Organ Sources; Recent Approvals; Approval Delays?; NIH's Open Access Policy Still Has Publishers Roiled; Tilting at the FDA